Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 395-398

  Risum, S ^a   Hogdall C ^b   Loft, A ^c   Berthelsen, A K ^c   Hogdall E ^d   Nedergaard, L ^b   Lundvall, L ^b   Engelholm, S A ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c Centre of Diagnostic Investigations   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

PET CT; Primary cytoreduction; Primary ovarian cancer; Stage migration; Survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 75949102368     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.008     Document Type: Article

References (38)

1. Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95 (2006) 161-192
2. Risum S., Hogdall C., Loft A., Berthelsen A.K., Hogdall E., Nedergaard L., et al. The diagnostic value of PET/CT for primary ovarian cancer-a prospective study. Gynecol. Oncol. 105 (2007) 145-149
3. Hicks R.J., Ware R.E., and Lau E.W. PET/CT: will it change the way that we use CT in cancer imaging?. Cancer Imaging 6 (2006) 52-62
4. Kitajima K., Murakami K., Yamasaki E., Kaji Y., Fukasawa I., Inaba N., et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 1912-1920
5. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312 (1985) 1604-1608
6. Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., and Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet. Gynecol. 93 (1999) 448-452
7. Kaplan E., and Meier P. Non-parametric estimation for incomplete observations. J. Am. Stat. Assoc. 53 (1959) 457-481
8. Cox D. Regression models and life tables. J. R. Stat. Soc. B. 34 (1972) 187-202
9. Vasey P.A. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J. Clin. Oncol. 21 (2003) 136-144
10. Curtin J.P., Malik R., Venkatraman E.S., Barakat R.R., and Hoskins W.J. Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64 (1997) 9-12
11. Liu P.C., Benjamin I., Morgan M.A., King S.A., Mikuta J.J., and Rubin S.C. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol. Oncol. 64 (1997) 4-8
12. Bonnefoi H., A'Hern R.P., Fisher C., Macfarlane V., Barton D., Blake P., et al. Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17 (1999) 767-775
13. Petru E., Luck H.J., Stuart G., Gaffney D., Millan D., and Vergote I. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur. J. Obstet. Gynecol. Reprod. Biol. 143 (2009) 69-74
14. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 (1999) 278-287
15. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer. Inst. Monogr. 42 (1975) 101-104
16. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol. Oncol. 38 (1990) 203-209
17. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979
18. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
19. Eisenkop S.M., Spirtos N.M., and Lin W.C. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol. 103 (2006) 329-335
20. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90 (2003) 390-396
21. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., bu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol. Oncol. 103 (2006) 559-564
22. Eisenhauer E.L., bu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 (2006) 1083-1090
23. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 (2006) 77-85
24. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol. Oncol. 100 (2006) 283-287
25. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., and du B.A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 106 (2007) 69-74
26. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol. Oncol. 105 (2007) 84-89
27. Vergote I., De I W., Tjalma W., Van G.M., Decloedt J., and van D.P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 (1998) 431-436
28. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von H.B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
29. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91 (2001) 2329-2334
30. Morice P., Dubernard G., Rey A., Atallah D., Pautier P., Pomel C., et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg. 197 (2003) 955-963
31. Everett E.N., French A.E., Stone R.L., Pastore L.M., Jazaeri A.A., Andersen W.A., et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am. J. Obstet. Gynecol. 195 (2006) 568-574
32. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103 (2006) 1070-1076
33. European Organization for Research and Treatment of Cancer: Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian cancer (EORTC protocol 55971). (http://www eortc be/protoc/Details asp?Protocol=55971) 2008.
34. Vergote I., De B.J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357 (2001) 176-182
35. Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J. Natl. Cancer Inst. 95 (2003) 113-125
36. Bertelsen K., Holund B., Andersen J.E., Nielsen K., Stroyer I., and Ladehoff P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int. J. Gynecol. Cancer 3 (1993) 211-218
37. Trope C., and Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J. Clin. Oncol. 25 (2007) 2909-2920
38. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., and Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115 (2009) 1234-1244